The TP53 gene, tobacco exposure, and lung cancer
暂无分享,去创建一个
[1] Y. Inayama,et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. , 1995, The American journal of pathology.
[2] K. Müller,et al. German uranium miner study--pathological and molecular genetic findings. German Uranium Miner Study, Research Group Pathology. , 1999, Radiation research.
[3] J. Minna,et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. , 1992, Oncogene.
[4] J. Roth,et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.
[5] Chinfei Chen,et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients , 2001, Environmental and molecular mutagenesis.
[6] U. Pastorino,et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. , 1992, Cancer research.
[7] J. Testa,et al. The pathogenesis of mesothelioma. , 2002, Seminars in oncology.
[8] C. Harris,et al. Radon and lung carcinogenesis: mutability of p53 codons 249 and 250 to 238Pu alpha-particles in human bronchial epithelial cells. , 1997, Carcinogenesis.
[9] S. Rodin,et al. Human lung cancer and p53: the interplay between mutagenesis and selection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Kalemkerian,et al. Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.
[11] Thierry Soussi,et al. The UMD-p 53 Database : New Mutations and Analysis Tools , 2003 .
[12] J. Minna,et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Y. Miller,et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. , 1997, The Journal of clinical investigation.
[14] W. Whong,et al. Distribution of p53 and K-ras mutations in human lung cancer tissues. , 1997, Carcinogenesis.
[15] O. V. Paklina,et al. [Atypical adenomatous hyperplasia of the lung]. , 2000, Arkhiv patologii.
[16] J. Jett,et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.
[17] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[18] Thierry Soussi,et al. TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.
[19] Takaaki Ito,et al. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. , 1999, American journal of clinical pathology.
[20] T. Mitsudomi,et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] J. Jen,et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. , 2000, Cancer research.
[22] I. Wistuba,et al. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas , 2000, International journal of cancer.
[23] J. Nikliński,et al. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. , 2001, The European respiratory journal.
[24] C. Harris,et al. p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. , 1996, Carcinogenesis.
[25] J. Minna,et al. p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.
[26] M. Olivier,et al. TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. , 2001, Mutagenesis.
[27] T. Allen-Mersh,et al. Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. , 1996, Gut.
[28] Jing Chen,et al. Distribution of p 53 and Kras mutations in human lung cancer tissues , 1997 .
[29] W. Travis,et al. Lung cancer , 1995, Cancer.
[30] Thierry Soussi,et al. The UMD‐p53 database: New mutations and analysis tools , 2003, Human mutation.
[31] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[32] M. Graffar. [Modern epidemiology]. , 1971, Bruxelles medical.
[33] K. Takami,et al. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs , 1998, Journal of surgical oncology.
[34] T Paschke,et al. Analysis of different versions of the IARC p53 database with respect to G-->T transversion mutation frequencies and mutation hotspots in lung cancer of smokers and non-smokers. , 2000, Mutagenesis.
[35] J. Herman,et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.
[36] J. Roth,et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.
[37] J. Minna,et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] C. Harris,et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.
[39] E. Wynder,et al. Differences in lung cancer risk between men and women: examination of the evidence. , 1996, Journal of the National Cancer Institute.
[40] K. Müller,et al. p53 gene mutation analysis in tumors of patients exposed to alpha-particles. , 1997, Carcinogenesis.
[41] C. Harris,et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. , 2001, Cancer research.
[42] R. Hruban,et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.
[43] P. Herrlich,et al. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. , 1995, Gut.
[44] N. Bouck. P53 and angiogenesis. , 1996, Biochimica et biophysica acta.
[45] Thierry Soussi,et al. Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.
[46] J. Gimferrer,et al. Atypical adenomatous hyperplasia of the lung problems in operative management. , 2000, Lung cancer.
[47] R. Herrmann,et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] A. Giatromanolaki,et al. p53 and angiogenesis in non-small-cell lung cancer. , 1998, British Journal of Cancer.
[49] R. Hruban,et al. p53 alterations in atypical alveolar hyperplasia of the human lung. , 1998, Human pathology.
[50] S. Norell,et al. Workbook of Epidemiology , 1995 .
[51] 北口 聡一. Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung , 1998 .
[52] R. Metcalf,et al. p53 protein accumulates frequently in early bronchial neoplasia. , 1993, Cancer research.
[53] 西﨑 正彦. Recombinant adenovirus expressing wild-type p53 is antiangiogenic : a proposed mechanism for bystander effect , 2000 .
[54] J. Minna,et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.
[55] Richard Doll,et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies , 2000, BMJ : British Medical Journal.
[56] P. Hainaut,et al. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.
[57] C. Harris,et al. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. , 1996, Preventive medicine.
[58] W. Travis,et al. Neuroendocrine Tumors of the Lung With Proposed Criteria for Large‐Cell Neuroendocrine Carcinoma: An Ultrastructural, Immunohistochemical, and Flow Cytometric Study of 35 Cases , 1991, The American journal of surgical pathology.
[59] G. Jacobson,et al. Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. , 1999, Journal of clinical pathology.
[60] B. You,et al. p53 gene mutations in asbestos associated cancers. , 1998, Biomedical and environmental sciences : BES.
[61] J. Roth,et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. , 1994, Cancer gene therapy.
[62] Jack A. Taylor,et al. p53 and K-ras in radon-associated lung adenocarcinoma. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[63] J. Jen,et al. Mutations in Non-Small Cell Lung Cancer p 53 Frequency of Alcohol Consumption and Cigarette Smoking Increase the Updated , 2000 .
[64] Yung‐Chie Lee,et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Tang,et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.
[66] Stephen S Hecht,et al. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. , 2002, The Lancet. Oncology.
[67] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[69] Molecular Damage in the Bronchial Epithelium of Current and Former Smokers , 1997 .
[70] P. Laurent-Puig,et al. TP53 and head and neck neoplasms , 2003, Human mutation.
[71] E. Mark,et al. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[72] K. Bielawski,et al. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer , 2002, Journal of Cancer Research and Clinical Oncology.
[73] G. Rechavi,et al. Absence of p53 mutations in malignant mesotheliomas. , 1997, American journal of respiratory cell and molecular biology.
[74] K. Kerr,et al. Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c‐erbB‐2 expression , 1994, The Journal of pathology.
[75] H. Bartsch,et al. Analysis of radon-associated squamous cell carcinomas of the lung for ap53 gene hotspot mutation , 2000, British Journal of Cancer.
[76] W. Hong,et al. Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.
[77] T. Soussi,et al. Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. , 1994, Chest.
[78] K. Vähäkangas. TP53 mutations in workers exposed to occupational carcinogens , 2003, Human mutation.
[79] I. Wistuba,et al. Genetic changes in the spectrum of neuroendocrine lung tumors , 1999, Cancer.
[80] J. Nikliński,et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. , 2001, Lung cancer.
[81] L. Mao. Molecular abnormalities in lung carcinogenesis and their potential clinical implications. , 2001, Lung cancer.
[82] C. Prives,et al. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells , 2002, Oncogene.
[83] E. Dmitrovsky,et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. , 1995, Cancer research.
[84] S. Payne,et al. 'Smoke like a man, die like a man'?: a review of the relationship between gender, sex and lung cancer. , 2001, Social science & medicine.